Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03012594 · ClinicalTrials.gov registry record · Phase 2
Lanreotide in the Treatment of Small Bowel Motility Disorders
A Phase 2 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03012594 is a Phase 2 study that has completed, run by Northwell Health. The registered enrollment target is 12 participants.
The verdict
NCT03012594, a Phase 2 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a human research study looking at the effectiveness of Lanreotide (study medication) in treating small bowel motility disorders. It is similar to a natural hormone somatostatin that is produced in the body in the stomach, duodenum, pancreas and brain. Somatostatin is a growth hormone-inhibiting hormone. Lanreotide is a man made hormone and is a long acting medication that is given once a month. It is marketed with a trade name "Somatuline Depot". It is given deep subcutaneously (deep within the layers of the skin) in the superior external quadrant of the buttock. Injection site will be alternated on subsequent injections.
Interventions
- DRUG Lanreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-05-11 |
| Est. Completion | 2019-03-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03012594
The ClinicalTrials.gov registry entry for NCT03012594 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lanreotide is the first listed.
NCT03012594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03012594 about?
NCT03012594 is a clinical study titled "Lanreotide in the Treatment of Small Bowel Motility Disorders". This is a human research study looking at the effectiveness of Lanreotide (study medication) in treating small bowel motility disorders. It is similar to a natural hormone somatostatin that is produced in the body in the stomach, duodenum, pancreas and brain. Somatostatin is a growth hormone-inhibit...
What is the current status of trial NCT03012594?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2017-05-11. Estimated completion is 2019-03-11.
What interventions are being tested in trial NCT03012594?
The interventions under investigation include: Lanreotide (DRUG).
Who is sponsoring clinical trial NCT03012594?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.